ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2019) 63 P173 | DOI: 10.1530/endoabs.63.P173

Biomarkers of myocardial fibrosis at coronary heart disease in the presence and absence of diabetes mellitus type 2

Alexey Korotaev, Andrey Prystrom, Lyudmila Korotaeva, Maria Rusalenko & Elena Naumenko


Repablican Scientific Center for Radiation Medicine and Human Ecology, Gomel, Belarus.


Combination of coronary heart disease (CHD) with diabetes mellitus type 2 significantly increases the risk of left ventricular remodeling. The objective of the study was to determine the association of biomarkers of myocardial fibrosis with the level of glycaemia at CHD in patients with and without DM type 2.

Methods: We have examined 104 patients with CHD of everage age 64.9±0.3 years old, 27 of them were with DM type 2; 77 patients were without DM type 2.

Results: The levels of glycaemia and HbA1c differed depending on the presence of DM type 2: 5.16 [4.7; 5.48] vs 6.70 [5.39; 7.40] mmol/l (P<0.001) and 5.70 [5.40; 5.93] vs 6.60 [5.80; 7.50]% (P<0.001). In the case if the CHD wasn’t combined with DM type 2, a correlation was found between the level of glycaemia and IL-1β (r=−0.30; P=0.007); IL-2 (r=−0.26; P=0.024); HbA1c with BNP (r=−0.42; P<0.001), galectin-3 (r=−0.30; P=0.008), IL-6 (r=−0.24; P=0.032), IL-12 (r=−0.26; P=0.023). When CHD was combined with T2DM, a correlation was found between the level of glycaemia and aldosterone (r=0.57; P=0.002); HbA1c with IL-1β (r=0.42; P=0.027), IL-6 (r=0.55; P=0.003) with aldosterone (r=0.56; P=0.002).

Conclusion: Patients with CHD showed a correlation between glycaemia and HbA1c levels with a number of biomarkers of myocardial fibrosis, regardless of the presence of DM type 2, which indicates the necessity to determine critical points of glycaemia and HbA1c, and perhaps of glycemia variability, which influence the myocardial fibrosis development.

Article tools

My recent searches

No recent searches.